TCTMD - tctmd.com
WEBGiven the growing prevalence of heart failure worldwide, we recognize a clear mandate for developing new monitoring strategies and treatment options to increase survival, decrease hospitalizations, and improve quality of life — and for achieving these goals via a variety of potential interventions that target the various contributors to heart ...
TCT 2024 - TCTMD.com
WEBTCTMD ® is produced by the Cardiovascular Research Foundation ® (CRF). CRF ® is committed to igniting the next wave of innovation in research and education that will help doctors save and improve the quality of their patients’ lives.
Slides | tctmd.com
WEBApr 8, 2024 · Interventional Complications 2023. Seattle, WA. July 14. July 15, 2023. See All Conferences. The best online resource for cardiology conference slides around the globe.
Full SELECT Results Affirm CV Risk Reduction With Semaglutide in ...
WEBNov 12, 2023 · The reduction in MACE (CV death, nonfatal MI, or nonfatal stroke) with semaglutide was seen during a mean follow-up of 39.8 months. Each component of the composite numerically favored active treatment, although only the difference in nonfatal MI reached significance: CV death (2.5% vs 3.0%; HR 0.85; 95% CI 0.71-1.01)
Going Contrast Free in TAVI Is Safe for CKD Patients
WEBAug 20, 2024 · Promising data for noncontrast CCTA are starting to build, with the latest study showing its role in balloon-expandable valves. With the right imaging strategy—one that avoids contrast media—patients with advanced chronic kidney disease (CKD) can safely undergo TAVI without putting undue strain …
FDA Approves First Transcatheter Tricuspid Valve Replacement …
WEBFeb 2, 2024 · In a surprise early-morning announcement, Edwards Lifesciences said the US Food and Drug Administration has approved the company’s Evoque tricuspid valve replacement system for the treatment of tricuspid regurgitation (TR). The approval is the first in the United States for a transcatheter tricuspid device. …
New Data Reassure on Rivaroxaban’s Role in Frail PAD Patients
WEBAug 19, 2024 · Rivaroxaban’s effect on the primary efficacy endpoint was not modified by frailty status: HR 0.93 (95% CI 0.75-1.15) in the frail group versus HR 0.83 (95% CI 0.72-0.97) in the nonfrail group (P for interaction = 0.37). The most notable benefits in frail patients on rivaroxaban were reductions in limb outcomes, including the composite of …
SUMMIT Meets Primary Endpoint for Safety, Efficacy of Tirzepatide ...
WEBAug 1, 2024 · The SUMMIT trial, the drug’s manufacturer announced today, met statistical significance for both of its primary endpoints. Tirzepatide reduced a composite of heart failure outcomes that included time to first occurrence of urgent HF visit, HF hospitalization, oral diuretic intensification, and CV death (HR 0.62; 95% CI 0.41-0.95) at a median ...
AHA Throws Its Support Behind New, Independent Medical Board
WEBOct 30, 2023 · AHA joins the “House of Cardiology” consortium’s push to leave ABIM’s certification process and create its own board. The American Heart Association (AHA) is joining several other professional societies in the quest for a new, independent medical board for cardiovascular medicine. Last week, the AHA’s national board of directors voted ...
Don’t Avoid Statins in Elderly, Frail Patients: Two Retrospective ...
WEBDec 15, 2023 · Statins reduce the risk of adverse cardiovascular events among older adults regardless of chronic kidney disease and frailty status, according to two new retrospective studies of US veterans. Researchers say their findings should encourage physicians to not be reluctant to give the lipid-lowering drugs to these populations.
Skip to content